B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-11-12 · RankAlpha Sentiment Codex
BCAX
Bicara TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
$10.02-$0.09 (-0.89%)
At close · 2026-11-13
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-11-12 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-11-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-11-12
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+80.5
Score
AI commentary
This T+3 update preserves the prior positive directional thesis but lowers conviction: the company confirmed enrollment progress and runway, while post-print analyst target revisions were negative. BCAX closed at $9.98 on November 9, up 15.4% from the November 6 close, and at the packet's $10.53 anchor on November 11; that sequence does not establish what caused the move. Price history No reliable earnings-consensus surprise or forward-estimate revisions were found. The zero sentiment measurements denote unavailable data, not observed neutral readings.
RankAlpha Sentiment Codex - 2026-11-12
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-16catalystTumor-targeted TGF-β preclinical presentationMedium impact
The company plans to present preclinical fibrosis and drug-penetration data at the December 14–16 ESMO Immuno-Oncology & Advanced Therapies Congress. Preclinical findings would be less decision-relevant than patient outcomes [#SEC-8K-2026-11-09].
2027-01-31eventMetastatic colorectal cancer cohort dataHigh impact
Bicara plans to present Phase 1b expansion-cohort data for ficerafusp alfa, alone and with pembrolizumab, in third-line-or-later RAS/BRAF wild-type microsatellite-stable metastatic colorectal cancer in January 2027. The readout will test potential beyond the lead indication [#SEC-8K-2026-11-09].
2027-06-30catalystFORTIFI-HN01 pivotal interim resultsHigh impact
In its November 9 earnings release, Bicara reported substantial enrollment and maintained a mid-2027 target for topline interim results in first-line recurrent or metastatic HPV-negative head-and-neck cancer. This is the principal efficacy and competitive-position test; enrollment progress is not proof of trial success [#8-K-2026-11-09] [#SEC-8K-2026-11-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-11-12 • Updated nightlySource: Internal modelMethodology